{"id":"doxercalciferol-capsules-hectorol","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypercalcemia"},{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Malaise"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxercalciferol is a prodrug that is converted in the liver to its active metabolite, 1,25-dihydroxyvitamin D2, which binds to the vitamin D receptor in target tissues. This activation increases intestinal calcium and phosphate absorption and suppresses PTH production, thereby normalizing serum calcium and phosphate levels in patients with secondary hyperparathyroidism.","oneSentence":"Doxercalciferol is a vitamin D analog that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone (PTH) secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:59.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis"},{"name":"Secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease not on dialysis"}]},"trialDetails":[{"nctId":"NCT02859896","phase":"PHASE3","title":"Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-01-19","conditions":"Secondary Hyperparathyroidism-Chronic Kidney Disease","enrollment":21},{"nctId":"NCT00463021","phase":"PHASE4","title":"A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-04","conditions":"Secondary Hyperparathyroidism","enrollment":36},{"nctId":"NCT00418600","phase":"PHASE4","title":"A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-11","conditions":"Secondary Hyperparathyroidism","enrollment":36},{"nctId":"NCT00601107","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2008-04","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"doxercalciferol capsules, Hectorol®","genericName":"doxercalciferol capsules, Hectorol®","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxercalciferol is a vitamin D analog that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone (PTH) secretion. Used for Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, Secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease not on dialysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}